HLA-G high-expressor 3’UTR markers are linked to gastric cancer development and survival
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03771-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Christian Vaquero-Yuste und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Inmunología, Oftalmología y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Stomach Neoplasms, HLA-G Antigens, 3' Untranslated Regions, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Real Colegio Complutense.
Abstract (Originalsprache)
Gastric cancer ranks fifth in both world prevalence and lethality, with a 5-year survival of less than 30%. HLA-G, a non-classical class I HLA gene, has emerged as a potential marker for cancer susceptibility and prognosis due to its immunomodulatory properties. Its level of expression is regulated by polymorphisms in the 3’ untranslated region (3’UTR) polymorphisms, which form various combined haplotypes (UTR-1 to -9). In this study, we examined HLA-G 3’UTR polymorphisms in paired tissue samples from 111 patients with gastric adenocarcinoma and 119 healthy controls. Polymorphism analysis was performed using PCR and Sanger sequencing, followed by statistical analysis using SNPStats software. Survival analysis was conducted using Kaplan–Meier curves and multivariate Cox regression models. High-expressor HLA-G 3’UTR haplotypes (UTR-1 and UTR-6) were significantly associated with gastric cancer susceptibility, indicating a potential role in tumor immune evasion. Additionally, the 14 base pair insertion/deletion polymorphism (14 bp I/D) emerged as a prognostic marker, with D/D genotype carriers showing lower survival rates compared to I/D and I/I genotype carriers. Our study highlights the clinical relevance of HLA-G polymorphisms in gastric cancer, suggesting their potential as prognostic markers and therapeutic targets. Further elucidation of HLA-G-related pathways could lead to personalized treatment strategies and improved patient outcomes in gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Inmunología, Oftalmología y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
- Departamento de Inmunología, Oftalmología y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain. ignajuar@ucm.es.
- Departamento de Estadística e Investigación Operativa, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
- Servicio de Cirugía General y Aparato Digestivo, Hospital Universitario Príncipe de Asturias, Madrid, Spain.
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
ORCID-Profile: Ignacio Juarez
Förderung
- Real Colegio Complutense
Zitieren
APA
Vaquero-Yuste, C., Juarez, I., Molina-Alejandre, M., Molanes-López, E. M., Gutiérrez-Calvo, A., López-García, A., Lasa, I., Gómez, R., Arnaiz-Villena, A., & Martín-Villa, J. M. (2024). HLA-G high-expressor 3’UTR markers are linked to gastric cancer development and survival. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03771-w
Vancouver
Vaquero-Yuste C, Juarez I, Molina-Alejandre M, Molanes-López EM, Gutiérrez-Calvo A, López-García A, et al. HLA-G high-expressor 3’UTR markers are linked to gastric cancer development and survival. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03771-w
BibTeX
@article{VaqueroYuste2024,
author = {Vaquero-Yuste, Christian and Juarez, Ignacio and Molina-Alejandre, Marta and Molanes-López, Elisa María and Gutiérrez-Calvo, Alberto and López-García, Adela and Lasa, Inmaculada and Gómez, Remedios and Arnaiz-Villena, Antonio and Martín-Villa, Jose Manuel},
title = {HLA-G high-expressor 3’UTR markers are linked to gastric cancer development and survival},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03771-w}
}
EUVIMED